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Background: At diagnosis, identiﬁcation of reliable biological indicators of prognosis to allow stratiﬁcation of patients
according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients.
This study aimed to explore the role of miR-34A expression on prognosis of EWS patients.
Patients and methods: Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with
neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases
were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months,
range 9–241 months). Expression of miR-34a and of some of its targets (cyclin D1, bcl-2, SIRT1 and YY1) was evaluated
by qRT-PCR using TaqMan MicroRNA Assays and/or by immunohistochemistry on tissue microarrays from the same
patients.
Results: High expression of miR-34a in localized tumors was signiﬁcantly related to better event-free and overall survival
(P = 0.004). Relevance of miR-34a was conﬁrmed by using different calibrators (normal mesenchymal stem cells and dif-
ferent normal tissues). By multivariate Cox regression analysis, low miR-34a expression as well as nontotal necrosis and
high levels of lactate dehydrogenase were all conﬁrmed as independent risk factors associated with poor outcome.
Expression of miR-34a was lower in metastases than in primary tumors. It inversely correlated with expression of cyclin
D1 and Ki-67.
Conclusions: By demonstrating its relationship with clinical outcome, we propose evaluation of miR-34a at diagnosis of
EWS patients to allow early risk stratiﬁcation. Validation of these results would nonetheless ultimately need a prospective
assessment.
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introduction
Ewing sarcoma (EWS) is the second most common tumor of bone
and soft tissue. It occurs mainly in children and young adults and
is characterized by a very aggressive nature with rapid growth and
a marked tendency to form distant metastases [1]. Treatment of
EWS is based on a combined approach of local therapy with
surgery and/or radiotherapy of the primary tumor and systemic
chemotherapy based on doxorubicin, vincristine, actinomycin D,
ifosfamide and etoposide [2]. Intensiﬁed chemotherapy regimens
with high doses have been used in patients with poor response to
standard chemotherapy leading to some improvements [3].
However, prolonged and intensive chemotherapy treatments are
characterized by toxicity and long-term adverse effects [4].
Moreover, cost-effectiveness of treatments is another important
problem for EWS patients [4], where cure mainly relies on public
investments. These two aspects render extremely important iden-
tiﬁcation of reliable indicators of prognosis, which may allow stra-
tiﬁcation of patients according to different risks at diagnosis. At
present, only clinico-pathological features, such as presence of clin-
ically evident metastases at diagnosis and poor response to neoad-
juvant chemotherapy are widely accepted as prognostic and
predictive factors in EWS [4]. In fact, despite many biological and
molecular markers have been proposed in past years [5, 6], their
clinical value still needs validation and experimental explanation.
We recently reported that high levels of miR-34a expression in
this tumor were associated with a more favorable clinical history
likely due to better responses to chemotherapy [7]. In order to
further assess its prognostic signiﬁcance, miR-34a expression
was analyzed in a larger series of 109 primary localized tumors
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from patients treated at a single institution from 1991 to 2009
and in 17 metastases. Analysis of some validated targets of miR-
34a (cyclin D1, bcl-2, SIRT1 and YY1) was also carried out.
materials andmethods
patient selection
Patients with localized EWS who were enrolled in prospective studies and
treated at the Rizzoli Institute were included in the present analysis.
The ethical committee of the Rizzoli Institute approved the studies, and
informed consent was obtained. Details about patients’ selection are pro-
vided in supplementary Material and Methods, available at Annals of
Oncology online.
sample processing and total RNA isolation
Total RNA from tumor samples was isolated from snap-frozen tissue mater-
ial using Trizol LS Reagent (Invitrogen, Carlsbad, CA). RNA quality and
quantity were assessed by NanoDrop analysis (NanoDrop ND1000
ThermoFisher Scientiﬁc, Waltham, MA) and/or by electrophoresis analysis
(1% agarose gel). To check whether extracted RNA was representative of
EWS cells, the tissue was morphologically analyzed after hematoxylin–eosin
staining (supplementary Figure S1, available at Annals of Oncology online)
before any processing and patients with nonrepresentative samples (33/142)
were excluded.
real time PCR
qRT-PCR analysis of miR-34a was carried out using TaqMan® MicroRNA
Assays and TaqMan® Universal PCR Master Mix, no AmpErase® UNG
(Applied Biosystems, Foster City, CA, USA) according to manufacturer’s
instructions. Primer sequences are available in supplementary Table S1,
available at Annals of Oncology online. Further details are provided in sup-
plementary Material and Methods, available at Annals of Oncology online.
Ki-67 staining
Avidin–biotin–peroxidase procedure was used. MAb (dilution 1:50) anti-Ki-
67 (MIB-1, Calbiochem-Novabiochem, San Diego, CA) was used as primary
antibody on tissue microarray (TMA) containing 58 EWS samples. Sections
(5 µm) from formalin-ﬁxed, parafﬁn-embedded tumor xenografts patients’
tumor blocks were placed on poly-L-lysine-coated slides (Sigma). Further
details are provided in supplementary Material and Methods, available at
Annals of Oncology online.
statistical methods
Details about statistical methods are provided in supplementary Material
and Methods, available at Annals of Oncology online.
results
expression of miR-34a in primary tumors predicts
Ewing sarcoma patient outcome
In keeping with its oncosuppressor role [8], miR-34a expression
was found to be generally lower in EWS with respect to several
normal controls, including human bone-marrow-, corion- or
dental pulp-derived mesenchymal stem cells, osteoblast precur-
sors as well as muscle and skin (supplementary Figure S2, avail-
able at Annals of Oncology online). Human mesenchymal
stem cell (hMSC) primary culture hMSC163 was used as repre-
sentative (Figure 1A): only a minority of patients (15/109, 14%)
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Figure 1. (A) Relative expression of miR-34a in 109 localized EWS primary tumors by using qRT-PCR. Human mesenchymal stem cell (hMSC) primary
culture hMSC163 was used as calibrator. (B) Prognostic impact of miR-34a expression according to Kaplan–Meier curves and log-rank test. High expressors
and low expressors were deﬁned according to the median value of −ΔΔCT. Event-free survival (EFS) or overall survival (OVS) was considered.
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had miR-34a expression levels remarkably higher (fold change
>2) than the normal control, while the others showed compar-
able or deﬁnitely lower levels. To establish clinical relevance of
miR-34a expression in EWS, the median was used as cutoff value
to stratify patients and deﬁne two categories of high or low
expressors, as previously reported [7]. Median follow-up of the
109 EWS patients was 67 months (range 9–241 months). Sixty-
eight patients (62%) remained continuously free of disease and
41 (38%) relapsed. First relapse pattern consisted of metastases
in 35 cases (lungs 17 cases, bones 8, lungs and bones 10), local
recurrence in 5, local recurrence and bone metastasis in 1. The
clinico-pathological characteristics are reported in Table 1.
Table 1. Clinico-pathological features of EWS patients evaluated for miR-34a expression by qRT-PCR in 109 tissue samples
Characteristics RT-PCR (N = 109) Association with prognosis Association with survival
N % EFSa OVSb
Gender
Female 31 28.4 P = 0.3 P = 0.4
Male 78 71.5
Age (years)
≤14 43 39.4 P = 0.9 P = 0.9
>14 66 60.6
Location
Extremity 84 77.1 P = 0.06 P = 0.2
Central 8 7.3
Pelvis 17 15.6
LDHc
Normal 72 73.5 P = 0.03 P = 0.0084
High 26 26.5
Surgery
YES 95 87.2 P = 0.08 P = 0.06
NO 14 12.8
Local treatment
RxT 14 12.8 P = 0.4 P = 0.2
RxT + surgery 17 15.6
Surgery 78 71.6
Chemo protocol
ISG/SSG III 85 78 P = 0.25 P = 0.35
Others 24 22
Response to chemotherapyd
Good 40 41.2 P = 0.0183 P = 0.018
Poor 57 58.8
Type of translocation
EWS/Fli-1 type I 56 51.4 P = 0.642 P = 0.304
EWS/Fli-1 nontype I 53 48.6
miR-34a
High 55 50.5 P = 0.0042 P = 0.0043
Low 54 49.5
EFS (status)
NED 68 62.4
REL 41 37.6
OVS (status)
Alive 75 68.8
Dead 34 31.2
Associations with prognosis were calculated by univariate analysis using the log-rank test. Results in bold are signiﬁcant at P≤ 0.05.
aEFS (median follow-up: 57 months; range 6–241 months).
bOVS (median follow-up: 67 months; range 9–241 months).
cData available for 98 patients in qRT-PCR.
dData available for 97 patients in qRT-PCR.
EWS, Ewing sarcoma; LDH, lactate dehydrogenase; RxT, radiotherapy; NED, no evidence of disease; REL, relapsed; EFS, event-free survival; OVS,
overall survival.
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Adverse events, occurred in 13 of 55 (24%) patients with high
expression of miR-34a but in 28 of 54 (52%) patients with low
expression (P = 0.003, Fisher’s exact test). Accordingly, tumor-
related deaths occurred in 11 of 55 (20%) high expressors but in
23 of 54 (43%) low expressors (P = 0.01, Fisher’s exact test).
Kaplan–Meier curves (Figure 1B) conﬁrmed that miR-34a ex-
pression in localized tumors is associated with a signiﬁcantly dif-
ferent risk of recurrence: 5-year event-free survival (EFS) was
74% for the 55 patients with high expression of miR-34a [95%
conﬁdence interval (CI) 62–82] while it was 51% for the
54 patients with low expression (95% CI 37–64) (P = 0.0071);
5-year overall survival (OVS) was 83% in high expressors (95%
CI 73–93) but it was 58% in low expressors (95% CI 44–71)
(P = 0.0027).
Considering the predictive signiﬁcance of tumor response to
induction chemotherapy, data were analyzed focusing on this
topic. miR-34a expression was similar in good and poor respon-
ders (data not shown). In good responder patients, the probabil-
ity of EFS and OVS were slightly better in case of high miR-34a
[5-year EFS: high miR-34a 86% (95% CI 70–100), how miR-34a
71% (95% CI 50–93), 5-year OVS: high miR-34a 90% (95% CI
77–100), low miR-34a 77% (95% CI 57–97)], without statistical
differences (5-year EFS: P = 0.2, 5-year OVS: P = 0.2). In poor
responder patients, the probability of EFS and OVS again were
better in case of high- miR-34a [5-year EFS: high miR-34a 67%
(95% CI 45–84), low miR-34a 45% (95% CI 27–64), 5-year
OVS: high miR-34a 90% (95% CI 66–96), low miR-34a 54%
(95% CI 35–73)], and the difference reached statistical signiﬁ-
cance (5-year EFS: P = 0.09, 5-year OVS: P = 0.05) in spite of the
relatively low number of patients.
To verify the reliability of this type of analysis, we also evalu-
ated whether the impact of miR-34a expression may vary by
changing the type of calibrator that was used to deﬁne the levels
of miR-34a expression. Despite the relative expression of miR-
34a in individual EWS patients differed when various normal
cells or tissues were used as calibrators (Figure 2A) (statistical
variability across the controls for expression of miR-34a was:
−ΔCT median = −2.740, standard deviation = 0.882), patients
deﬁned with high expression of miR-34a according to the differ-
ent median values (supplementary Table S2, available at Annals
of Oncology online) always maintained a signiﬁcantly lower
probability to face adverse events. Representative Kaplan–Meier
survival curves obtained by using corion-derived hMSCs as cali-
brator are shown in Figure 2B.
Low miR-34a expression, poor response of tumors after
neoadjuvant chemotherapy and high LDH values, which
resulted signiﬁcantly associated with worse clinical outcome in
univariate analysis (Table 1), were all conﬁrmed as independent
risk factors associated with poor outcome by multivariate Cox’s
proportional hazards regression analysis (Table 2). Fisher’s
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Figure 2. (A) Relative expression of miR-34a in 109 primary EWS samples compared with 16 different calibrators (COR3386; COR3442; hMSC195;
hMSC196; WJ3530; WJMSC; DP3; DP15; AM3388; AM3484; BM3380; BM3491; osteoblast precursors; muscle; skin; pool hMSC). (B) Prognostic impact of
miR-34a expression according to Kaplan–Meier curves and log-rank test using corion-derived hMSCs (COR3386) as calibrator. High expressors and low
expressors were deﬁned according to the median value of −ΔΔCT. Event-free survival (EFS) or overall survival (OVS) was considered.
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exact test analysis conﬁrmed that miR-34a expression did not
correlate with any of the clinico-pathological characteristics of
EWS patients at study entry (supplementary Table S3, available
at Annals of Oncology online).
expression of miR-34a in Ewing sarcoma
metastases
RNAs from 5 bone and 12 lung metastases were available and
used for miR-34a analysis. miR-34a expression was signiﬁcantly
lower in metastases compared with primary tumors (supple-
mentary Figure S3, available at Annals of Oncology online)
(P = 0.022, Mann–Whitney U-test).
expression of miR-34a correlates with proliferation
rate of EWS samples
To further validate the clinical relevance of miR-34a, we also
analyzed by qRT-PCR the expression of some genes that were
reported to be targeted by miR-34a [9, 10], including the evalu-
ation of (i) cyclin D1, a cell cycle regulator [11], (ii) bcl-2, a
major antiapoptotic driver [12], (iii) the transcription factor Yin
Yang 1 (YY1), which controls several divergent cellular pro-
cesses, including cell proliferation and apoptosis [13] and pro-
motes p53 degradation [13], (iv) SIRT1, a NAD-dependent
deacetylase that deactivates p53 [14, 15]. Statistically signiﬁcant
inverse correlations (supplementary Table S4, available at
Annals of Oncology online) were observed between miR-34a
levels and expression of cyclin D1 (r = −0.242, P = 0.0114,
Spearman’s test), bcl-2 (r = −0.182, P = 0.0589) and YY1
(r =−0.200, P = 0.0369), which indeed appeared as molecular hubs
of the putative complex network of genes regulated by miR-34a
(supplementary Figure S4, available at Annals of Oncology online,
GeneGo network analysis). However, at protein level, when cyclin
D1, bcl-2 and YY1 were evaluated on TMA created with
matching tumor samples (58 cases), the expression of miR-34a
was found to maintain statistically signiﬁcant inverse cor-
relation only with cyclin D1 expression (r = −0.27, P < 0.05,
Pearson’s correlation test, supplementary Table S5, available at
Annals of Oncology online). Accordingly, miR-34a expression
was evaluated in paired samples and found to inversely correlate
with Ki-67 staining (r = −0.31, P = 0.02, Pearson’s correlation
test).
discussion
A large number of studies have demonstrated that altered ex-
pression of speciﬁc miRNAs plays an important role in human
tumorigenesis [16]. Detection of aberrant miRNA expression
levels either in tumors or more recently in blood could be used
for prediction of prognosis because miRNAs are stable, resistant
to several harsh conditions, and can be detected easily and
cheaply by reliable and quantitative methods. Our previous
miRNA array data in EWS tissue samples have indicated the
possible prognostic relevance of miR-34a. High expression of
miR-34a at diagnosis was found to be associated with better
outcome [7]. Although interesting, this ﬁrst evidence warrants
further examination in larger cohorts in order to obtain a more
general acknowledgement from pathologists and oncologists of
the clinical value of miR-34a. Validation of experimental results
is always a difﬁcult task in rare tumors. Combination of samples
from different institutions may have signiﬁcant drawbacks in
terms of local treatments and/or sample preservation. In con-
trast, analysis of larger series from single institutions implicates
analysis of samples from different decades.
In this study, we analyzed the expression of miR-34a in a
retrospective series of 109 tumors, strictly controlled either in
terms of clinical or technical parameters and ﬁtting the stan-
dards for reporting prognostic biomarkers (REMARK guide-
lines) [17]. In line with its role as a master driver of tumor
suppression, miR-34a expression was found to be generally
downregulated in EWS compared with normal tissue or mesen-
chymal stem cells, which very likely represent the cell of origin
of EWS [18]. Expression of miR-34a was lower in metastases
compared with primary tumors. In addition, when miR-34a
levels were evaluated at diagnosis in localized tumors, they were
associated with a signiﬁcantly different outcome: higher levels
correlated with a lower risk to develop secondary events. This
evidence was conﬁrmed also when different types of normal
calibrators were considered. This is an important point because
it indicates that, despite the quantiﬁcation of miR-34a obtained
by quantitative PCR is relative, the use of different normal
samples do not alter net results: patients with a higher expres-
sion of miRNA have a more favorable outcome. For perspective
studies, the use of digital, which provides absolute rather than
relative quantiﬁcation of nucleic acids PCR [19], may be useful
to solve the problem of the deﬁnition of a threshold level for
miR-34a.
MiR-34a can antagonize many different oncogenic processes
by regulating genes that function in various cellular pathways
[20]. A major function of miR-34a is the control of cellular pro-
liferation: ectopic expression of miR-34a in cancer cells
decreases cell doubling times and leads to G1/G2 arrest.
Accordingly, transcripts validated for their interactions with
miR-34a include cyclin D1 and E2 as well as cyclin-dependent
kinases 4 and 6, all genes involved in promoting cell cycle.
Moreover, miR-34a is also involved in regulation of apoptosis: it
is transcriptionally induced by p53 and is an important effector
Table 2. Multivariate analysis using Cox’s proportional hazards
regression analysis
RR 95% CI P value
Variables associated with better EFS
miR-34a: high expression 0.406 0.244–1.033 0.0177
LDH: normal expression 0.389 0.184–0.821 0.0132
Necrosis: total 0.086 0.012–0.639 0.0165
Variables associated with better OVS
miR-34a: high expression 0.372 0.159–0.873 0.023
LDH: normal expression 0.316 0.140–0.714 0.006
Necrosis: total 0.001 0.001–1000 0.962
Adjusted risk-rate (RR) ratio of relapse was estimated for the
variables that resulted to be signiﬁcantly associated with prognosis
by univariated analysis.
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in the execution of p53 signaling because it represses Bcl-2,
SIRT1 and YY1. Although the ability of miR-34a to impact
these cellular processes may suggest that it can act in synergism
with conventional cytotoxic therapies, as previously conﬁrmed
in experimental conditions in various tumors including EWS
[7], no relation was found between miR-34a expression and
pathological response of the primary tumor to induction
chemotherapy in our series of patients. The expression of miR-
34a better discriminate prognosis in patients with poor rather
than good responses to chemotherapy. Considering that these
patients were treated with high-dose chemotherapy, high miR-
34a expression very likely characterizes patients whose tumors
have a lower biological aggressiveness, in particular a lower pro-
pensity to metastasize rather than a higher chemosensitivity.
In our samples, it appears that miR-34a function in cell cycle
and proliferation is prevalent with respect to apoptosis control.
Signiﬁcant correlations with cyclin D1 and with Ki-67 staining
were indeed observed both at mRNA and protein level. At clin-
ical level, the relevance of miR-34a may thus be complemented
by Ki-67 expression, which was previously shown to constitute
a valuable indicator of poor prognosis in localized EWS [21].
At biological level, however, these evidences may highlight a
more complex relationship, which deserves further investiga-
tions. Cyclin D1 is expressed at much higher levels in EWS
when compared with cancers devoid of EWS fusions and bone-
marrow mesenchymal stem cells from which Ewing tumors are
thought to originate [22]. EWS-FLI1, the genetic hallmark of
EWS, is known to affect transcription and alternative process-
ing of cyclin D1 transcripts, both of which favor EWS cell
transformation [22]. Besides its well-deﬁned role in regulating
cell cycle, cyclin D1 is indeed involved in several other crucial
processes, including induction of cellular migration and inva-
sion, enhancement of angiogenesis, inhibition of mitochondrial
metabolism, enhancement of DNA damage sensing and DNA
damage repair [11]. Our data showed a correlation between
miR-34a and cyclin D1 expression. We can speculate that miR-
34a may counteract the action of EWS-FLI1 by reducing the
expression of a critical driver of EWS transformation also in
presence of the oncogene. In addition, cyclin D1 has been
recently found to induce expression of Dicer, a central regulator
of miRNA maturation [23], and thereby promotes maturation
of miRNA [23]. This new evidence indicates the existence of a
complex crosstalk between cyclin D1 and expression of the
noncoding genome. Likely, when expression of miR-34a is
higher in EWS tumors, cyclin D1 could not evade negative
feedback from the noncoding genome and its expression is
reduced.
Hence, although we acknowledge the limits that may be
related to a retrospective although well-controlled study, we con-
sider that miR-34a constitutes a valuable indicator of good prog-
nosis in localized EWS and strongly recommend its detection in
a prospective series of patients. Upregulation of miR-34a in
tumors that do not express it could be of great therapeutic inter-
est. Nanotechnology-based approaches and in particular stable
nucleic acid lipid particles, which are characterized by good
transfection efﬁciency and stability in serum, have been recently
proposed as effective agents to deliver miR-34a in vivo [24], thus
representing a promising tool for miRNA-therapeutics against
tumors.
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On demand Gamma-Knife strategy can be safely
combined with BRAF inhibitors for the treatment
of melanoma brain metastases
C. Gaudy-Marqueste1,†*, R. Carron2,†, C. Delsanti2, A. Loundou3, S. Monestier1, E. Archier1,
M. A. Richard1, J. Regis2 & J. J. Grob1
Departments of 1Dermatology and Skin Cancers, UMR911 CRO2; 2Stereotaxic and Functional Neurosurgery, Gammaknife Unit, Inserm U751; 3Public Health, Aix-Marseille
University, APHM, Marseille, France
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Background: Both Gamma-Knife radiosurgery (GKRS) and BRAF inhibitors (BRAF-I) have been shown to be useful in
melanoma patients with brain metastases (BMs), thus suggesting that it could be interesting to combine their respective
advantages. However, cases of radiosensitization following conventional radiation therapy in BRAF-I treated patients have
raised serious concerns about the real feasibility and risk/beneﬁt ratio of this combination.
Patients and methods: Review by two independent observers of brain magnetic resonance imaging (MRI) follow-up
pictures, and volume and edema quantiﬁcations, and survival assessment in all patients who had been treated by GKRS
and BRAF-I at a single institution.
Results: Among 53 GKRS carried out in 30 patients who ever received BRAF-I and GKRS, 33 GKRS were carried out in
24 patients while under BRAF-I treatment, from which only 4 with an interruption of BRAF-I. The 20 other GKRS were
carried out in 15 patients (including 9 of the 24) before initiation of BRAF-I treatment. No case of radiation-induced necro-
sis and no scalp radiation dermatitis occurred. A >20% increase in volume was observed in 35 of the 263 BM treated by
GKRS (13.3%), but only 3 clear-cut edemas and 3 hemorrhages were detected within 2 months after GKRS, and
4 edemas and 7 hemorrhages later. Neither the MRI features nor the incidence of the volume changes, hemorrhage and
edema were deemed unexpected for melanoma BM treated by GKRS. Median survival from ﬁrst GKRS under BRAF-I
and ﬁrst dose of BRAF-I were 24.8 and 48.8 weeks, respectively.
Conclusion: This series does not show immediate radiotoxicity nor radiation recall, in melanoma patients with BRAF-I
whose BMs are treated by GKRS. Interrupting BRAF-I for stereotactic radiosurgery (SRS) of BM seems useless, although
it is still advised for other radiation therapies. The potential beneﬁt of combining SRS and BRAF-I can be safely tested.
Key words: BRAF inhibitors, Gamma-Knife radiosurgery, radiosensitization, brain metastasis, metastatic melanoma
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